Literature DB >> 20191573

Preventing hepatitis B reactivation in immunosuppressed patients: is it time to revisit the guidelines?

Jinoos Yazdany, Leonard Calabrese.   

Abstract

Entities:  

Mesh：

Year:  2010        PMID： 20191573      PMCID： PMC2924189          DOI： 10.1002/acr.20167

Source DB:  PubMed          Journal:  Arthritis Care Res (Hoboken)        ISSN： 2151-464X            Impact factor:   4.794


× No keyword cloud information.
  35 in total

1.  Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving rituximab.

Authors:  I Dervite; D Hober; P Morel
Journal:  N Engl J Med       Date:  2001-01-04       Impact factor: 91.245

2.  Hepatitis B reactivation in a chronic hepatitis B surface antigen carrier with rheumatoid arthritis treated with infliximab and low dose methotrexate.

Authors:  P Ostuni; C Botsios; L Punzi; P Sfriso; S Todesco
Journal:  Ann Rheum Dis       Date:  2003-07       Impact factor: 19.103

3.  Fulminant hepatitis subsequent to reactivation of precore mutant hepatitis B virus in a patient with lymphoma treated with chemotherapy and rituximab.

Authors:  José-Angel Hernández; Raúl Diloy; David Salat; Neus del Río; Xavier Martínez; Josep-María Castellví
Journal:  Haematologica       Date:  2003-06       Impact factor: 9.941

4.  Fatal hepatitis B virus reactivation by an escape mutant following rituximab therapy.

Authors:  Timm H Westhoff; Friederike Jochimsen; Alexander Schmittel; Marina Stoffler-Meilicke; Jurgen H Schafer; Walter Zidek; Wolfram H Gerlich; Eckhard Thiel
Journal:  Blood       Date:  2003-09-01       Impact factor: 22.113

5.  Development of fulminant hepatitis B (precore variant mutant type) after the discontinuation of low-dose methotrexate therapy in a rheumatoid arthritis patient.

Authors:  S Ito; K Nakazono; A Murasawa; Y Mita; K Hata; N Saito; M Kikuchi; K Yoshida; M Nakano; F Gejyo
Journal:  Arthritis Rheum       Date:  2001-02

6.  Safety of disease modifying anti-rheumatic agents in rheumatoid arthritis patients with chronic viral hepatitis.

Authors:  M Y Mok; W L Ng; M F Yuen; R W Wong; C S Lau
Journal:  Clin Exp Rheumatol       Date:  2000 May-Jun       Impact factor: 4.473

7.  Safety of anti-TNF-alpha therapy in rheumatoid arthritis and spondylarthropathies with concurrent B or C chronic hepatitis.

Authors:  C H Roux; O Brocq; V Breuil; C Albert; L Euller-Ziegler
Journal:  Rheumatology (Oxford)       Date:  2006-04-07       Impact factor: 7.580

Review 8.  Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures.

Authors:  D Lavanchy
Journal:  J Viral Hepat       Date:  2004-03       Impact factor: 3.728

9.  Infliximab therapy for rheumatic diseases in patients with chronic hepatitis B or C.

Authors:  Owonayo Oniankitan; Christophe Duvoux; Dominique Challine; Arianne Mallat; Xavier Chevalier; Jean-Michel Pawlotsky; Pascal Claudepierre
Journal:  J Rheumatol       Date:  2004-01       Impact factor: 4.666

10.  Prevalence, risk factors and evaluation of a screening strategy for chronic hepatitis C and B virus infections in healthy company employees.

Authors:  V Sypsa; E Hadjipaschali; A Hatzakis
Journal:  Eur J Epidemiol       Date:  2001       Impact factor: 8.082
View more
  5 in total

1.  Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis.

Authors:  Maya H Buch; Josef S Smolen; Neil Betteridge; Ferdinand C Breedveld; Gerd Burmester; Thomas Dörner; Gianfranco Ferraccioli; Jacques-Eric Gottenberg; John Isaacs; Tore K Kvien; Xavier Mariette; Emilio Martin-Mola; Karel Pavelka; Paul P Tak; Desiree van der Heijde; Ronald F van Vollenhoven; Paul Emery
Journal:  Ann Rheum Dis       Date:  2011-03-06       Impact factor: 19.103

Review 2.  Leveraging the electronic health record to improve quality and safety in rheumatology.

Authors:  Gabriela Schmajuk; Jinoos Yazdany
Journal:  Rheumatol Int       Date:  2017-08-29       Impact factor: 2.631

3.  Gaps in Ambulatory Patient Safety for Immunosuppressive Specialty Medications.

Authors:  Sarah Patterson; Gabriela Schmajuk; Michael Evans; Ishita Aggarwal; Zara Izadi; Milena Gianfrancesco; Jinoos Yazdany
Journal:  Jt Comm J Qual Patient Saf       Date:  2019-01-25

4.  Past hepatitis B virus infection in rheumatoid arthritis patients receiving biological and/or nonbiological disease-modifying antirheumatic drugs.

Authors:  Shunsuke Mori
Journal:  Mod Rheumatol       Date:  2011-04-29       Impact factor: 3.023

5.  Hepatitis B Serology in Patients with Rheumatic Diseases.

Authors:  Martin Feuchtenberger; Arne Schäfer; Axel Philipp Nigg; Michael Rupert Kraus
Journal:  Open Rheumatol J       Date:  2016-08-31
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.